Penumbra, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited, compared with Q1 2023. Penumbra is a global medical-device company focused on interventional therapies. It reports one operating segment.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $278.7 million | $241.4 million | +15.4% |
| Gross profit / margin | $181.1 million / 65.0% | $151.1 million / 62.6% | Margin +2.4 percentage points |
| Operating income / margin | $12.1 million / 4.3% | $8.0 million / 3.3% | Improved |
| Net income | $11.0 million | $8.6 million | +28.5% |
| Diluted EPS | $0.28 | $0.22 | +$0.06 |
| Operating cash flow | $38.3 million | $13.1 million | +$25.2 million |
Thrombectomy revenue rose 29.5% to $187.7 million, driven mainly by U.S. sales and further market penetration; U.S. thrombectomy sales increased 35.2%. Embolization and access revenue declined 5.7% to $91.0 million, primarily due to international products. U.S. revenue increased 22.0% to $209.6 million; international revenue was nearly flat at $69.0 million and represented 24.8% of total revenue, versus 28.8% a year earlier.
Gross margin improved with favorable product mix, productivity improvements and higher volume. Operating expenses increased 18.2% to $169.0 million: R&D rose 23.2% to $24.6 million and SG&A rose 17.3% to $144.4 million. Net income growth also reflected higher interest and other income ($2.5 million versus $0.6 million), while the effective tax rate increased to 24.8% from 1.0%.
Cash, liquidity and obligations
At March 31, 2024, cash and cash equivalents were $223.1 million and marketable investments were $90.4 million; working capital was $782.2 million. Cash increased $55.6 million during the quarter. Operating cash flow included an $11.6 million inventory build, partly offset by collections and payment timing. Investing cash flow was $18.4 million, mainly reflecting net maturities of marketable investments, partly offset by a $10.0 million strategic investment and $5.8 million of capital expenditures.
The filing reports no outstanding borrowings and states that the $100 million revolving credit agreement matured on February 16, 2024 and was not renewed. Lease liabilities totaled $231.4 million, including current and non-current operating and finance leases. Management believes current liquidity is sufficient for at least the next 12 months.
Material developments, outlook and risks
- SG&A included $4.8 million of non-recurring litigation-related costs. In an April 22, 2024 mediation, Penumbra agreed to a $4.6 million aggregate settlement of California wage-and-hour matters, subject to a final agreement and court approval; the company accrued $4.6 million at quarter-end.
- Penumbra entered a new China technology-licensing arrangement during the quarter, with fixed payments upon technology transfer and regulatory support.
- No specific financial guidance was provided. Management expects continued investment in product launches, manufacturing, R&D, IT and international expansion. It notes potential quarterly variability from product and geographic mix, product introductions, competition, reimbursement, regulatory timing, supply and costs, and foreign exchange.
- International sales are principally denominated in local currencies, primarily euros; the company does not currently hedge foreign-exchange exposure. Management said a hypothetical 10% adverse currency move would not materially affect net income.
- The company cited competitive pressures and dependence on successful new-product adoption and transition, salesforce effectiveness, clinical evidence and healthcare reimbursement. It reported no material changes to previously disclosed risk factors.
Investor facts to verify
- Whether the $4.6 million wage-and-hour settlement receives court approval and whether final costs differ from the recorded accrual.
- Whether thrombectomy growth continues and offsets weakness in embolization and access, particularly internationally.
- Whether improved gross margin is sustained as product mix, production costs and new-product launches evolve.
- How inventory investment, collections and payment timing affect operating cash flow and liquidity in subsequent quarters.
- How the higher effective tax rate, stock-based compensation and foreign-exchange movements affect future earnings.